Novo Nordisk
Institution - official statements with no named speaker · DNK
Track record: No forecast checked yet (161 not due, 40 being checked).
201forecasts & commitments on the record
84%can be checked as stated
40average ambiguity (0-100)
0goalpost moves recorded
0confirmed U-turns
Timeline
came true partly did not not due / being checked / too vague
Calibration score: shown after 10 checked forecasts with a stated likelihood (now 0).
How they speak about the future: based on data 200, stated on authority 1.
Kinds of claim: forecast 196, mixed claim 3, commitment 2. · Download this report card as a picture
In the nine words
How to read this
Each box is one sentence a public figure or institution said about the future, word for word, with a link to the official text. Can be checked means it names what will happen, by when, and how likely - so it can be compared with official figures later. Too vague to check means it does not. Ambiguity (0-100) is how many different ways the sentence can be read. When the date passes, the forecast is compared with official data and marked came true, partly or did not come true. Labels judge the sentence, never the person. Full guide and glossary.On the record (201)
Adjusted operating profit growth is now expected to be -2% to +2% at CER.
Adjusted sales growth is now expected to be -2% to +2% at CER, with fluctuations in growth rates expected across quarters.
•Adjusted sales growth for 2026 is now expected to be -2% to +2% at CER and adjusted operating profit growth is now expected to
ongoing, and pending regulatory decision, a US launch is expected in H1 2027.
The change in list prices is expected to impact Novo's cash flow in 2027.
The 2030 ambitions are not a projection of Novo's financial outlook or expected growth.
Adjusted operating profit growth is now expected to be 0% to -6% at CER.
Adjusted sales growth is now expected to be 0% to -6% at CER, with fluctuations in growth rates expected across quarters.
The interim dividend for 2026 will be paid in August 2026.
•Adjusted sales growth for 2026 is now expected to be 0% to -6% at CER and adjusted operating profit growth is now expected to be 0% to -6% at CER.
The change in list prices is expected to impact Novo Nordisk's cash flow in 2027.
Novo Nordisk continues the execution of the share repurchase programme of DKK 11,200,000,010.45 initiated on 6 May 2026, and ending on 1 February 2027 under the overall DKK 15 billion 2026 programme, in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of …
As part of this, a new share repurchase programme for an amount up to DKK 11,200,000,010.45 will be initiated 6 May 2026 and ending on 1 February 2027 in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the …
For Wegovy® pill, pending regulatory decisions, Novo Nordisk expects to launch in the first markets outside the US during the second half of 2026.
•Adjusted operating profit growth, also excluding the 340B provision reversal, is now expected to be -4 to -12% at CER.
•Adjusted sales growth for 2026, which excludes the 340B provision reversal, is now expected to be -4 to -12% at CER.
•Pending regulatory decisions, the first Wegovy® pill launches outside the US are expected during the second half of 2026.
Given the current exchange rates versus the Danish krone, adjusted sales growth reported in Danish kroner is expected to be 3 percentage points lower than at CER, primarily due to depreciation of the USD/DKK exchange rate.
Adjusted sales growth is expected to be -5% to -13% at CER, with fluctuations in growth rates expected across quarters.
Adjusted operating profit growth reported in Danish kroner is expected to be 5 percentage points lower than at CER.
Adjusted operating profit growth is expected to be -5 to -13% at CER.
Adjusted sales growth reported in Danish kroner is expected to be 3 percentage points lower than at CER.
•Adjusted sales growth for 2026, which excludes revenue from the reversal of 340B provisions, is expected to be -5 to -13% at CER.
Given the current exchange rates versus the Danish krone, sales growth reported in Danish kroner is now expected to be 4 percentage points lower than at CER.
Sales growth is now expected to be 8-11% at CER.
Sales and operating profit growth reported in Danish kroner is now expected to be 4 and 6 percentage points lower than at CER, respectively.
•For the full-year 2025 outlook, sales growth is now expected to be 8-11% at CER with operating profit growth now expected to be 4-7% also at CER, including a negative full-year impact of around DKK 8 billion from the company-wide transformation.
Also, it was announced that Helena Saxon (independent) will be proposed for election as member of the Board at the Annual General Meeting in 2026.
Also for 2026, the announced acquisition of Akero Therapeutics, Inc. is expected to lead to increased research and development costs, with an estimated negative impact on full-year operating profit growth in 2026 of around 3 percentage points, depending on the timing of closing.
–Interim dividend for 2025 of DKK 3.75 for each Novo Nordisk A and B share of DKK 0.10 will be paid in August 2025.
With more than one billion people living with obesity globally, including more than 100 million living in the US, and only a few million on treatment, I am confident that under Mike Doustdar's leadership, Novo Nordisk will maximise the significant growth opportunities, supported by a strong product portfolio and future pipeline".
Sales and operating profit growth reported in Danish kroner is now expected to be 3 and 5 percentage points lower than at CER, respectively.
•For the 2025 outlook, sales growth is now expected to be 8-14% at CER, and operating profit growth is now expected to be 10-16% at CER.
Lars Fruergaard Jørgensen, president and CEO: "While delivering 18% sales growth in the first half of 2025, we have lowered our full-year outlook due to lower growth expectations for our GLP-1 treatments in the second half of 2025.
The lowered sales outlook for 2025 is driven by lower growth expectations for the second half of 2025, reflecting the persistent use of compounded GLP-1s, slower-than-expected market expansion and competition.
Given the current exchange rates versus the Danish krone, sales growth reported in DKK is expected to be 3 percentage points lower than at CER, primarily due to depreciation of the USD/DKK exchange rate.
Sales growth is now expected to be 13% to 21% at CER.
•For the 2025 outlook, sales growth is now expected to be 13-21% at CER, and operating profit growth is now expected to be 16-24% at CER.
Novo Nordisk still expects to file for the first regulatory approval of CagriSema during the first quarter of 2026.
While Novo Nordisk maintains our global aspiration of a minimum 45% representation for each gender by the end of 2025, Novo Nordisk's operations in the U.S. will no longer participate in this global initiative due to evolving legal requirements.
Given the current exchange rates versus the Danish krone, sales growth reported in DKK is expected to be 3 percentage points higher than at CER.
Sales growth is expected to be 16% to 24% at CER.
Sales and operating profit growth reported in Danish kroner is expected to be 3 and 5 percentage points higher than at CER, respectively.
•For the 2025 outlook, sales growth is expected to be 16-24% at CER, and operating profit growth is expected to be 19-27% at CER.
Further, the aim is that goods and services from suppliers will be based on 100% sourced renewable power by 2030.
In order to secure supply chain readiness, Novo Nordisk now expects to file for the first regulatory approval of CagriSema during the first quarter of 2026.
Sales growth is now expected to be 23% to 27% at CER.
The fulfilment of various customary closing conditions is progressing, and Novo Nordisk still expects that the acquisition will be completed towards the end of 2024.
Growth reported in Danish kroner is now expected to be 1 percentage point lower than at CER growth for sales and 2 percentage points lower for operating profit.
•For the 2024 outlook, sales growth is now expected to be 23-27% at CER, and operating profit growth is now expected to be 21-27% at CER.
Showing the newest 50 - the ledger has all 201.